289 related articles for article (PubMed ID: 33690190)
1. Nanostructured lipid carrier co-delivering paclitaxel and doxorubicin restrains the proliferation and promotes apoptosis of glioma stem cells via regulating PI3K/Akt/mTOR signaling.
Chang L; Zhang Y; Li M; Zhao X; Wang D; Liu J; Zhou F; Zhang J
Nanotechnology; 2021 Mar; 32(22):. PubMed ID: 33690190
[TBL] [Abstract][Full Text] [Related]
2. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect.
Wang Y; Zhang H; Hao J; Li B; Li M; Xiuwen W
Drug Deliv; 2016 May; 23(4):1398-403. PubMed ID: 26079530
[TBL] [Abstract][Full Text] [Related]
3. Xihuang Pill-destabilized CD133/EGFR/Akt/mTOR cascade reduces stemness enrichment of glioblastoma via the down-regulation of SOX2.
Xu L; Duan H; Zou Y; Wang J; Liu H; Wang W; Zhu X; Chen J; Zhu C; Yin Z; Zhao X; Wang Q
Phytomedicine; 2023 Jun; 114():154764. PubMed ID: 36963368
[TBL] [Abstract][Full Text] [Related]
4. Nanocarrier-Based Combination Chemotherapy for Resistant Tumor: Development, Characterization, and Ex Vivo Cytotoxicity Assessment.
Raikwar S; Vyas S; Sharma R; Mody N; Dubey S; Vyas SP
AAPS PharmSciTech; 2018 Nov; 19(8):3839-3849. PubMed ID: 30280350
[TBL] [Abstract][Full Text] [Related]
5. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment.
Cui Y; Xu Q; Chow PK; Wang D; Wang CH
Biomaterials; 2013 Nov; 34(33):8511-20. PubMed ID: 23932498
[TBL] [Abstract][Full Text] [Related]
6. The anti-tumor and renoprotection study of E-[c(RGDfK)
Zhang B; Zhang Y; Dang W; Xing B; Yu C; Guo P; Pi J; Deng X; Qi D; Liu Z
J Nanobiotechnology; 2022 Sep; 20(1):425. PubMed ID: 36153589
[TBL] [Abstract][Full Text] [Related]
7. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells.
Zhang XG; Miao J; Dai YQ; Du YZ; Yuan H; Hu FQ
Int J Pharm; 2008 Sep; 361(1-2):239-44. PubMed ID: 18586075
[TBL] [Abstract][Full Text] [Related]
8. Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling.
Hou Y; Sun B; Liu W; Yu B; Shi Q; Luo F; Bai Y; Feng H
Theranostics; 2021; 11(2):555-566. PubMed ID: 33391492
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer.
Yang XY; Li YX; Li M; Zhang L; Feng LX; Zhang N
Cancer Lett; 2013 Jul; 334(2):338-45. PubMed ID: 22776563
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody.
Abdolahpour S; Toliyat T; Omidfar K; Modjtahedi H; Wong AJ; Rasaee MJ; Kashanian S; Paknejad M
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):89-94. PubMed ID: 28296511
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-30a suppresses self-renewal and tumorigenicity of glioma stem cells by blocking the NT5E-dependent Akt signaling pathway.
Peng L; Ming Y; Zhang L; Zhou J; Xiang W; Zeng S; He H; Chen L
FASEB J; 2020 Apr; 34(4):5128-5143. PubMed ID: 32067282
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
[TBL] [Abstract][Full Text] [Related]
13. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA.
Shao Z; Shao J; Tan B; Guan S; Liu Z; Zhao Z; He F; Zhao J
Int J Nanomedicine; 2015; 10():1223-33. PubMed ID: 25709444
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity.
Lages EB; Fernandes RS; Silva JO; de Souza ÂM; Cassali GD; de Barros ALB; Miranda Ferreira LA
Biomed Pharmacother; 2020 Dec; 132():110876. PubMed ID: 33113428
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel inhibits proliferation and invasion and promotes apoptosis of breast cancer cells by blocking activation of the PI3K/AKT signaling pathway.
Li G; Xu D; Sun J; Zhao S; Zheng D
Adv Clin Exp Med; 2020 Nov; 29(11):1337-1345. PubMed ID: 33269821
[TBL] [Abstract][Full Text] [Related]
16. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.
Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X
Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Glioma Cells' Proliferation by Doxorubicin-Loaded Exosomes via Microfluidics.
Thakur A; Sidu RK; Zou H; Alam MK; Yang M; Lee Y
Int J Nanomedicine; 2020; 15():8331-8343. PubMed ID: 33149579
[TBL] [Abstract][Full Text] [Related]
18. Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells.
Zhou J; Sun M; Jin S; Fan L; Zhu W; Sui X; Cao L; Yang C; Han C
Drug Deliv; 2019 Dec; 26(1):281-289. PubMed ID: 30880491
[TBL] [Abstract][Full Text] [Related]
19. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.
Li Y; Hou H; Zhang P; Zhang Z
Drug Deliv; 2020 Dec; 27(1):1044-1053. PubMed ID: 32633576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
